Clinical Trials · NCT02210871
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 44
- Start date
- Aug 2014
- Locations
- 4 sites, Poland, Slovakia
- Primary endpoint
- Area under the semaglutide plasma concentration-time curve